<SEC-DOCUMENT>0001144204-18-050538.txt : 20180924
<SEC-HEADER>0001144204-18-050538.hdr.sgml : 20180924
<ACCEPTANCE-DATETIME>20180924170649
ACCESSION NUMBER:		0001144204-18-050538
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20180920
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20180924
DATE AS OF CHANGE:		20180924

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			APPLIED DNA SCIENCES INC
		CENTRAL INDEX KEY:			0000744452
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MISCELLANEOUS BUSINESS SERVICES [7380]
		IRS NUMBER:				592262718
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36745
		FILM NUMBER:		181084130

	BUSINESS ADDRESS:	
		STREET 1:		50 HEALTH SCIENCES DRIVE
		CITY:			STONY BROOK
		STATE:			NY
		ZIP:			11790
		BUSINESS PHONE:		631-240-8800

	MAIL ADDRESS:	
		STREET 1:		50 HEALTH SCIENCES DRIVE
		CITY:			STONY BROOK
		STATE:			NY
		ZIP:			11790

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PROHEALTH MEDICAL TECHNOLOGIES INC
		DATE OF NAME CHANGE:	20010504

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DCC ACQUISITION CORP
		DATE OF NAME CHANGE:	19990211

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DATALINK CAPITAL CORP/TX/
		DATE OF NAME CHANGE:	19980306
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tv503382_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WASHINGTON, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO SECTION 13 OR 15(d) OF THE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Date of Report (Date of earliest event reported):
September 20, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Applied DNA Sciences, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%; padding-right: 3pt; padding-left: 3pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Delaware</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or other jurisdiction<BR>
        of incorporation)</P></TD>
    <TD STYLE="width: 34%; padding-right: 3pt; padding-left: 3pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>001-36745</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Commission File Number)</P></TD>
    <TD STYLE="width: 33%; padding-right: 3pt; padding-left: 3pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>59-2262718</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(IRS Employer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Identification No.)</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>50 Health Sciences Drive</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Stony Brook, New York 11790</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address of principal executive offices;
zip code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Registrant&rsquo;s telephone number, including
area code: <B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>631-240-8800</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>N/A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Former name or former address, if changed
since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%; padding-right: 3pt; padding-left: 3pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 3pt; padding-left: 3pt; font-size: 10pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="width: 96%; padding-right: 3pt; padding-left: 3pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27.35pt; text-indent: -27.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%; padding-right: 3pt; padding-left: 3pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 3pt; padding-left: 3pt; font-size: 10pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="width: 96%; padding-right: 3pt; padding-left: 3pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27.35pt; text-indent: -27.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%; padding-right: 3pt; padding-left: 3pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 3pt; padding-left: 3pt; font-size: 10pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="width: 96%; padding-right: 3pt; padding-left: 3pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27.35pt; text-indent: -27.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%; padding-right: 3pt; padding-left: 3pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 3pt; padding-left: 3pt; font-size: 10pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="width: 96%; padding-right: 3pt; padding-left: 3pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter). Emerging growth company
</FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 7.01 Regulation FD Disclosure.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 20, 2018, Applied DNA Sciences,
Inc. (the &ldquo;Company&rdquo;) issued a press release announcing that LineaRx, Inc. (&ldquo;LineaRx&rdquo;), its wholly-owned
subsidiary focused on next-generation biotherapeutics, had signed a Joint Development Agreement (the &ldquo;Agreement&rdquo;) with
Takis S.R.L. and its subsidiary Evvivax S.R.L. (&ldquo;Takis/Evvivax&rdquo;). Takis/Evvivax are biotechnology companies focused
on the discovery and development of DNA based anti-cancer vaccines for the human and animal markets, respectively. Under the terms
of the Agreement, LineaRx and Takis/Evvivax will jointly develop linear DNA expression vectors for two of Takis/Evvivax&rsquo;s
anti-cancer vaccine candidates utilizing LineaRx&rsquo;s linear DNA technology. A copy of the press release is filed as Exhibit
99.1 to this Current Report on Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The information in Item 7.01of this Current
Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed &ldquo;filed&rdquo; for purposes of Section
18 of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;) or otherwise subject to the liabilities
of that section, nor shall it be deemed to be incorporated by reference in any registration statement or other document filed under
the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise stated in such filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 9.01. Financial Statements and Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(<I>d) Exhibits</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; padding-right: 3pt; font-size: 10pt"><A HREF="tv503382_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></A></TD>
    <TD STYLE="width: 94%; padding-right: 3pt; padding-left: 3pt; font-size: 10pt; text-align: justify"><A HREF="tv503382_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release of Applied DNA Sciences, Inc. dated September 20, 2018 regarding the joint development agreement among LineaRx, Inc., Takis S.R.L. and Evvivax S.R.L.</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 39.65pt">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: September 24, 2018</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">APPLIED DNA SCIENCES, INC.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 51%; padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="width: 6%; padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="width: 43%; padding-right: 3pt; padding-left: 3pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ James A. Hayward</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">James A. Hayward</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%; padding-right: 3pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit Number</B></FONT></TD>
    <TD STYLE="width: 92%; padding-right: 3pt; padding-left: 3pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; font-size: 10pt"><A HREF="tv503382_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></A></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; font-size: 10pt; text-align: justify"><A HREF="tv503382_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release of Applied DNA Sciences, Inc. dated September 20, 2018 regarding the joint development agreement among LineaRx, Inc., Takis S.R.L. and Evvivax S.R.L.</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tv503382_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Applied DNA Subsidiary, LineaRx, Inc. Signs
Joint Development</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Agreement with Takis and Evvivax to Develop<BR>
Linear-DNA Based Anti-Cancer Vaccines</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #0070C0"><I><BR>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #0070C0"><I>Collaboration Seeks to Develop PCR-produced Linear DNA as a Safer Expression Vector for Vaccines</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>STONY BROOK N.Y., September 20, 2018</B> &ndash; Applied
DNA Sciences Inc. (NASDAQ: APDN) (&ldquo;Applied DNA&rdquo; or the &ldquo;Company&rdquo;) announced today that LineaRx, Inc. (&ldquo;LineaRx&rdquo;),
its wholly-owned subsidiary focused on next-generation biotherapeutics, has signed a Joint Development Agreement (the &ldquo;Agreement&rdquo;)
with Takis S.R.L. and Evvivax S.R.L. (&ldquo;Takis/Evvivax&rdquo;), biotechnology companies focused on the discovery and development
of DNA based anti-cancer vaccines for the human and animal markets, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under the terms of the Agreement, LineaRx and Takis/Evvivax
will jointly develop linear DNA expression vectors for two of Takis/Evvivax&rsquo;s anti-cancer vaccine candidates utilizing LineaRx&rsquo;s
linear DNA technology. Linear DNA amplicons carrying the DNA sequences for Takis/Evvivax vaccine candidates will be delivered to
preclinical animal models via Takis/Evvivax&rsquo;s proprietary electroporation technology. Antigen-specific immune responses aimed
at achieving therapeutic effects will be studied.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The previously announced collaboration between the companies
has already shown promise of yielding immunity in mice that were DNA-vaccinated against the human protein telomerase, which is
over-expressed in more than 85% of all cancers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dr. Luigi Aurisicchio, CEO of Takis/Evvivax stated: &ldquo;We
are excited to co-develop linear DNA expression vectors for our DNA vaccine candidates with LineaRx. Initial data from the use
of LineaRx&rsquo;s amplicons in our vaccine candidates is promising. The advantages of linear DNA over plasmids would provide a
clear market edge over plasmid-based DNA sources. We look forward to a mutually beneficial collaboration&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;This Agreement serves to validate LineaRx&rsquo;s technology
as critical and necessary to the field of biotherapeutics in its ability to deliver potentially powerful approaches to the treatments
of chronic diseases,&rdquo; stated Dr. James Hayward, president and CEO of Applied DNA. &ldquo;Takis/Evvivax are ideal partners
of LineaRx given their innovative anti-cancer vaccine candidates for both humans and animals together with their expertise in preclinical
animal models.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dr. Hayward continued, &ldquo;The use of PCR-produced linear
DNA, as opposed to bacterially produced plasmids, is an innovative concept that provides the potential for increased patient safety,
ease of manufacture and vaccine logistics, and reduced costs. Our know-how in the fields of bulk linear DNA production and in bioconjugate
chemistry enable us to create novel and highly efficient expression vectors.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">With their stability at room temperature, low risk of infection
or secondary illness, and stability during transportation, DNA vaccines overcome many of the undesirable properties of conventional
vaccines. The global DNA based human vaccine market is expected to grow at a CAGR of 55% and reach a value of $2.7 billion by 2019<FONT STYLE="font-size: 10pt"><SUP>1</SUP></FONT>.
The global veterinary vaccine market is expected to reach $20.6 billion by 2021<FONT STYLE="font-size: 10pt"><SUP>2</SUP></FONT>,
with DNA based animal vaccines gaining rapid market share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Takis/Evvivax emerged from a Merck-supported research center
in Rome and has relationships across Big Pharma (http://www.takisbiotech.it/en/takis-services). The companies have agreed to seek
sponsorship for their work together.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About LineaRx </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">LineaRx seeks to commercialize the biotherapeutic value of Applied
DNA&rsquo;s deep expertise and experience in the design, manufacture and chemical modification of DNA by large scale polymerase
chain reaction (&ldquo;PCR&rdquo;). Linear DNA is a form of DNA distinct from the circular form of DNA most commonly produced in
plasmids and grown in bacteria. Plasmids are extrachromosomal DNA found in bacteria and are associated with the genes for antibiotic
resistance which are often exchanged between bacteria and consequentially, are seen by many to embody a serious threat to global
health. In addition, many nucleic acid-based therapies also rely on viral vectors for efficient transfection and expression of
plasmid DNA. These viral vectors carry additional nontrivial risks and are extremely time consuming and expensive to manufacture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In all forms of gene therapy, DNA exerts its influence from
within the nucleus. Recombinant events for circular DNA are permanent and alter the genomes of the affected cells and their progeny.
The fundamental challenge of all gene and cellular therapies is safety. Recent studies have elaborated &ldquo;unintended consequences&rdquo;
when plasmid and viral vectors are combined that may pose future risks for treated patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 20%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>1</SUP></FONT>
https://www.bccresearch.com/market-research/biotechnology/dna-vaccines-bio067b.html</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>2</SUP></FONT>
https://globenewswire.com/news-release/2018/01/22/1298446/0/en/Worldwide-Veterinary-animal-Vaccine-Market-to-Surpass-USD-12-10-Bn-by-2021.html</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">When linear DNA enters the nucleus, it does not need to be incorporated
into the genome in to be temporarily expressed as the intended proteins product. LineaRx posits that for the effectiveness of genetic
vaccines or genetic immune therapies, transient expression may be sufficient.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Applied DNA Sciences</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Applied DNA is a provider of molecular
technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and DNA mass
production for diagnostics and therapeutics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Applied DNA makes life real and safe
by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply
chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion. The
proprietary DNA-molecular based &ldquo;CertainT<SUP>&reg;</SUP>&rdquo; platform can be used to identify, tag, test, and track products,
to help assure authenticity, origin, traceability, sustainability and quality of products. SigNature<SUP>&reg;</SUP>&nbsp;DNA describes
the core technology ingredient that is at the heart of a family of uncopyable, security and authentication solutions such as SigNature<SUP>&reg;</SUP>&nbsp;T
and fiberTyping<SUP>&reg;</SUP>, targeted toward textiles and apparel, BackTrac&trade; and DNAnet<SUP>&reg;</SUP>, for anti-theft
and loss prevention, and digitalDNA<SUP>&reg;</SUP>, providing powerful track-and-trace. All provide a forensic chain of evidence,
and can be used to prosecute perpetrators. Applied DNA Sciences is also engaged in the large-scale production of specific DNA sequences
using the polymerase chain reaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Visit&nbsp;<U>adnas.com</U>&nbsp;for
more information. Follow us on&nbsp;<U>Twitter</U>&nbsp;and&nbsp;<U>LinkedIn</U>. Join our&nbsp;<U>mailing list</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Common stock listed on NASDAQ under
the symbol APDN, and warrants are listed under the symbol APDNW.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><B>Forward Looking Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">The statements made by
Applied DNA in this press release may be &quot;forward-looking&quot; in nature within the meaning of the Private Securities Litigation
Act of 1995.&nbsp;Forward-looking&nbsp;statements describe Applied DNA&rsquo;s future plans, projections, strategies and expectations,
and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA.
Actual results could differ materially from those projected due to our history of losses, limited financial resources, limited
market acceptance, shifting enforcement priorities of US federal laws relating to cannabis, and various other factors detailed
from time to time in Applied DNA's SEC reports and filings, including our Annual Report on Form 10-K filed on December 28, 2017and
our subsequent quarterly reports on Form 10-Q filed on February 8, 2018, May 3, 2018 and August 13, 2018, which are available at&nbsp;www.sec.gov</FONT><FONT STYLE="background-color: white">.
APDN undertakes no obligation to update publicly any&nbsp;</FONT>forward<FONT STYLE="background-color: white">-</FONT>looking<FONT STYLE="background-color: white">&nbsp;statements
to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless
otherwise required by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Evvivax S.R.L. and Takis S.R.L.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">EVVIVAX,
whose name is derived from Engineered Veterinary Vectored Immunotherapy and Vaccines, is a spin-off of Takis Biotech</FONT><FONT STYLE="background-color: white">.
EVVIVAX pursues the discovery and development of innovative Therapeutic Veterinary Cancer Vaccines based on viral vectors and DNA
platform technologies. EVVIVAX frontline candidates are two therapeutic cancer vaccines for canine tumors: Tel-eVax and Erb-eVax.
EVVIVAX aims at translating scientific breakthrough achievements in Cancer Immunotherapy into marketed innovative products in Veterinary
and subsequently in Human Oncology. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">Visit
www.evvivax.com for more information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">Takis
is a Biotech Company created in November 2009 by a group scientists from IRBM, a Research Center in near Rome, formerly part of
the global network of Merck Research Laboratories (MRL). The group has more than 15 years of experience and an established track
record in drug discovery in Oncology and is recognized for the conception and implementation of a number of innovative technologies.
One of the main assets of Takis is the expertise in <I>in vivo</I> electro-gene-transfer, which can be used for a variety of clinically
useful applications, from vaccine development to somatic gene therapy. Takis pipeline include four Cancer Vaccine candidates based
on this technology. Takis is also actively involved in the generation of humanized monoclonal antibodies for use in Oncology and
Infectious Diseases. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Visit www.takisbiotech.it for more information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>investor contact: </B>Sanjay M. Hurry, LHA Investor Relations,
212-838-3777, shurry@lhai.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>media contact</B>: Cheryl Schneider, Dian Griesel Int&rsquo;l,
212-825-3210, <FONT STYLE="background-color: white">cschneider@dgicomm.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>program contact: </B>Brian Viscount, 631 240 8877, brian.viscount@adnas.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>web:&nbsp;</B>www.adnas.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>twitter: </B>@APDN</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  L LX# 2(  A$! Q$!_\0
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M6",[2<NW0<4TFW9";25V7:***0PHHHH ***CCGBE:18Y4=HVVN%8$J?0^AH
MDHHHH **** "BBB@ HK*\0>(M,\,Z8U_JEP(H@<*H&7D;^ZH[FO#_$_Q4\2:
MY!(^FQ3:7I6[9YL2DNQ]&DZ ^P_,T >V:WXLT+PZI.J:G! ^,B+=ND/T49/Z
M55\*>-M)\8B\.F"X'V1E5_.CVY#9P1R>.#[UXKX)TGP)J<JR^(=;N#>N<M!/
MF&,GWDR=WYBO;O"NG0:;9S16FGV=I:E\Q&U Q(/4D$[N,<F@#?HHHH ****
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M_P#SPE_[]FJY:?9?@3S3[LLG7=5_Y_I?T_PIIU[5?^?Z7]/\*K&VG_Y]YO\
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M_P"@Q<_^._X4A\9^)/\ H,W/_CO^%9AL+W_GRNO^_+?X4TV%[_SY77_?EO\
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M+]9\07L>K>.+V>0 #;:M+ND8=@Q'"CV'/TKV&""*VMXX((UBAC4(B(,!0.@
MJ2B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
